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Emergence of multi-drug resistant tuberculosis (MDR-TB) and HIV-TB co-infections
potentiate the development of newer antitubercular agents to combat against tuberculosis,
a dreadful disease. In the present investigation a series of pyrazoline analogues were
designed and synthesized based on the structure of known antitubercular agent thiace-
tazone, in hope of obtaining new and safe antitubercular agents. The target molecules were
synthesized in two steps, starting with the condensation of 4-aminoacetophenone and p-
anisidine in methanolic sodium hydroxide solution followed by the cyclization of inter-
mediate chalcones with appropriate semicarbazide/thiosemicarbazide in glacial acetic
acid. All the synthesized compounds were characterized by 1H NMR, IR and mass spectral
data and the purity of the compounds was checked by elemental analysis. Their anti-
mycobacterial activity was evaluated by two folds serial dilution method. 3-(4-
Aminophenyl)-N-(4-chlorophenyl)-4,5-dihydro-5-(4-methoxyphenyl)pyrazole-1-
carboxamide (4i) showed maximum activity against Mycobacterium tuberculosis H37Rv with
minimum inhibitory concentration (MIC) of 7.41 mM.
Copyright 2015, Beni-Suef University. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).1. Introduction
Mycobacterium tuberculosis (MTB), one among the dreadful
pathogens is mainly responsible for tuberculosis (TB) in
human. An estimated 8.6 million new cases of TB and 1.3
million deaths occurred globally in 2012 (World Health6; fax: þ91 144 5121120.
(M.J. Ahsan).
i-Suef University.
ity. Production and hostin
/licenses/by-nc-nd/4.0/).Organization, Global Tuberculosis Report; 2013). After 40
years since the discovery of rifampin, US-FDA has granted
conditional approval of TMC207 as a part of combination
therapy to treat adults with multi-drug resistant (MDR-TB) in
December 2012 and then later approved by EuropeanMedicine
Agency (EMA) in March 2014 (Kamal et al., 2006; http://
www.fda.gov; http://www.ema.europa.eu). However nausea,g by Elsevier B.V. This is an open access article under the CC BY-
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ders, and QT interval prolongation has been detected in pa-
tients receiving this drug (Matteelli et al., 2010). EMA has also
granted conditional approval of delamanid for the treatment
of MDR-TB in April 2014 (Ryan and Lo, 2014; http://
www.ema.europa.eu/docs/en). The emergence of MDR-TB
and HIV-TB co-infection reduces the success rate of Directly
Observed Treatment Short course (DOTS) in controlling TB.
Also the combination of second line drug with DOTS has sig-
nificant side effects. Hence it is clear that development of
newer antitubercular drugswith novelmechanism of action is
today's urgent need to fight against TB.
Pyrazoline analogues are an important class of heterocycles
and possess significant biological activities including anticon-
vulsant (Ahsan et al., 2013, 2012a; Ahsan, 2013), antimicrobial
(Dawane et al., 2010; Ahsan et al., 2012a), anticancer (Ahsan,
2012), antitubercular (Ahsan et al., 2011a, 2011b, 2011c, 2012b),
anti-inflammatory (Sharma et al., 2010), antiviral (Ahsan et al.,
2012a; Mui et al., 2002), antidepressant (Bilgin et al., 1993), anti-
arrhythmic (Turan-Zitouni et al., 2000), neuroprotective (Ahsan,
2013) etc. In the present investigation the pharmacophore of
thiacetazone was taken and pyrazoline analogues were syn-
thesized.Thedesignof thepyrazoline scaffold is shown inFig. 1.2. Experimental
2.1. General
All chemicals were either supplied by E. Merck (Germany) or S.
D. Fine Chemicals (India). Themelting point of the compounds
was determined by open tube capillary method and is un-
corrected. The progress of reactions was monitored by TLC
plates (silica gel G) using eluants benzeneeacetone (9:1), and
the spots were identified by iodine vapours or UV light. IR
spectra were recorded on a Schimadzu 8201 PC, FT-IR spec-
trometer (KBr pellets). 1H NMR spectra were recorded in
DMSO-d6 on a Bruker AC 400 MHz spectrometer using TMS as
internal standard andmass spectra were recorded on a Bruker
Esquire LCMS using ESI.
2.2. General procedure for the synthesis of (2E)-1-(4-
aminophenyl)-3-(4-methoxyphenyl)prop-2-ene-1-one (3)
4-aminoacetophenone (50 mmol; 6.76 g) with 4-
methoxybenzaldehyde (50 mmol; 6.81 g) in diluted meth-
anolic sodium hydroxide solution was stirred under room
temperature for 4 h. The resulting solution was allowed to
standovernight and then the reactionmixturewaspoured into
cold water and neutralized with dilute HCl. The solid wasN
N
H
O
Thiacetaz4a
N NH2N
O
NH2
S
Fig. 1 e Design of the title compounds (4a-l)filtered,driedand recrystallizedwithethanol toobtain the (2E)-
1-(4-aminophenyl)-3-(4-methoxyphenyl)prop-2-ene-1-one (3).
2.3. General procedure for the synthesis 3-(4-
aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide analogues (4a-l)
1-(4-Aminophenyl)-3-(4-methoxyphenyl)prop-2-ene-1-one (3)
(2 mmol; 0.51 g) and thiosemicarbazide/semicarbazide/
substituted phenyl semicarbazides (2 mmol) in 20 ml glacial
acetic acid was refluxed for 12 h. The excess of solvent was
removed under reduced pressure and then the reaction
mixture was poured into the crushed ice. The solid mass was
filtered, dried and recrystallized with ethanol furnished the 3-
(4-Aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-pyr-
azole-1-carboxamide/carbothioamide analogues (4a-l).
2.3.1. 3-(4-Aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-
1H-pyrazole-1-carbothioamide (4a)
(Thitipone et al., 2013).
2.3.2. 3-(4-Aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-
1H-pyrazole-1-carboxamide (4b)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.04 (1H, dd, J ¼ 3.07,
10.91 Hz, Ha), 3.77 (3H, s, OCH3), 3.78 (1H, dd, J ¼ 6.14, 11.84 Hz,
Hb), 5.45 (1H, t, J ¼ 7.46 Hz, Hx), 6.41 (2H, s, NH2), 6.85e6.87 (2H,
d, J¼ 8.31Hz, ArH), 7.08e7.10 (2H, d, J¼ 7.89Hz, ArH), 7.67e7.72
(4H, m, ArH), 6.52 (2H, bs, CONH2);
13C NMR (100 MHz, DMSO
d6): dH (ppm) 162.1, 158.6, 151.7, 150.6, 135.9, 130.1, 128.0, 124.1,
116.5, 114.0, 61.1, 55.8, 39.5; IR (KBr) (nmax, cm
1): 3304 (NH),
1665 (C]O), 1594 (C]N); EI-MS, m/z: 310 (Mþ).
2.3.3. 3-(4-Aminophenyl)-5-(4-methoxyphenyl)-N-phenyl-
4,5-dihydro-1H-pyrazole-1-carboxamide (4c)
(Sayed et al., 1996).
2.3.4. 3-(4-Aminophenyl)-5-(4-methoxyphenyl)-N-(p-tolyl)-
4,5-dihydro-1H-pyrazole-1-carboxamide (4d): 1H NMR
(400 MHz, DMSO d6)
dH (ppm) 2.09 (3H, s, CH3), 3.04 (1H, dd, J ¼ 3.06, 10.99 Hz, Ha),
3.79 (1H, dd, J¼ 3.84, 11.02 Hz, Hb), 3.82 (3H, s, OCH3), 5.41 (1H, t,
J ¼ 7.89 Hz, Hx), 6.49 (2H, s, NH2), 7.00e7.02 (2H, d, J ¼ 8.33 Hz,
ArH), 7.70e7.84 (8H,m, ArH), 8.10e8.13 (2H, d, J¼ 8.77 Hz, ArH),
10.29 (1H, s, CONH); IR (KBr) (nmax, cm
1): 3302 (NH), 1667
(C]O), 1591 (C]N); EI-MS, m/z: 400 (Mþ).
2.3.5. 3-(4-Aminophenyl)-5-(4-methoxyphenyl)-N-(o-tolyl)-
4,5-dihydro-1H-pyrazole-1-carboxamide (4e)
1H NMR (400 MHz, DMSO d6): dH (ppm) 2.11 (3H, s, CH3), 3.03
(1H, dd, J ¼ 3.16, 11.83 Hz, Ha), 3.78 (1H, dd, J ¼ 3.81, 11.01 Hz,N NH2N
O
N
H
O
NH
NH2
S
Isosteric replacement of "S" with "O"
one
Ar
4b-l
based on the structure of thiacetazone.
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NH2), 7.01e7.03 (2H, d, J¼ 8.49 Hz, ArH), 7.72e7.81 (8H,m, ArH),
8.02e8.04 (2H, d, J ¼ 8.79 Hz, ArH), 10.26 (1H, s, CONH); IR (KBr)
(nmax, cm
1): 3302 (NH), 1680 (C]O), 1592 (C]N); EI-MS, m/z:
400 (Mþ).
2.3.6. 3-(4-Aminophenyl)-N-(2,4-dimethylphenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4f)
1H NMR (400 MHz, DMSO d6): dH (ppm) 2.09 (3H, s, CH3), 2.35
(3H, s, CH3) 3.07 (1H, dd, J ¼ 3.19, 11.08 Hz, Ha), 3.77 (1H, dd,
J ¼ 3.91, 10.99 Hz, Hb), 3.82 (3H, s, OCH3), 5.42 (1H, t, J ¼ 8.49 Hz,
Hx), 6.51 (2H, s, NH2), 7.00e7.02 (2H, d, J ¼ 8.77 Hz, ArH),
7.70e7.84 (7H,m, ArH), 8.10e8.12 (2H, d, J¼ 8.33 Hz, ArH), 10.29
(1H, s, CONH); IR (KBr) (nmax, cm
1): 3314 (NH), 1675 (C]O),
1592 (C]N); EI-MS, m/z: 414 (Mþ).
2.3.7. 3-(4-Aminophenyl)-N-(2,6-dimethylphenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4g)
1H NMR (400 MHz, DMSO d6): dH (ppm) 2.35 (6H, s, CH3), 3.07
(1H, dd, J ¼ 3.19, 11.08 Hz, Ha), 3.77 (1H, dd, J ¼ 3.91, 10.99 Hz,
Hb), 3.82 (3H, s, OCH3), 5.42 (1H, t, J ¼ 8.69 Hz, Hx), 6.52 (2H, s,
NH2), 7.00e7.02 (2H, d, J¼ 8.33 Hz, ArH), 7.70e7.84 (7H,m, ArH),
8.10e8.13 (2H, d, J ¼ 8.33 Hz, ArH), 10.29 (1H, s, CONH); IR (KBr)
(nmax, cm
1): 3312 (NH), 1678 (C]O), 1592 (C]N); EI-MS, m/z:
414 (Mþ).
2.3.8. 3-(4-Aminophenyl)-N-(4-fluorophenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4h)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.03 (1H, dd, J ¼ 3.89,
11.12 Hz, Ha), 3.77 (1H, dd, J ¼ 3.99, 11.09 Hz, Hb), 3.83 (3H, s,
OCH3), 5.41 (1H, t, J ¼ 8.93 Hz, Hx), 6.51 (2H, s, NH2), 7.02e7.04
(2H, d, J¼ 8.33 Hz, ArH), 7.65e7.77 (8H,m, ArH), 8.09e8.11 (2H, d,
J ¼ 8.33 Hz, ArH), 10.19 (1H, s, CONH); IR (KBr) (nmax, cm1): 3310
(NH), 1679 (C]O), 1591 (C]N), 783 (C-F); EI-MS, m/z: 404 (Mþ).
2.3.9. 3-(4-Aminophenyl)-N-(4-chlorophenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4i)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.06 (1H, dd, J ¼ 3.88,
10.91 Hz, Ha), 3.77 (1H, dd, J ¼ 3.95, 11.01 Hz, Hb), 3.83 (3H, s,
OCH3), 5.41 (1H, t, J ¼ 8.91 Hz, Hx), 6.50 (2H, s, NH2), 7.02e7.04
(2H, d, J ¼ 8.39 Hz, ArH), 7.67e7.81 (8H, m, ArH), 8.02e8.04 (2H,
d, J ¼ 8.37 Hz, ArH), 10.19 (1H, s, CONH); 13C NMR (100 MHz,
DMSO d6): dH (ppm) 160.1, 158.7, 151.8, 150.7, 135.8, 134.1, 130.3,
129.9, 129.1, 128.1, 124.1, 123.3, 116.4, 114.1, 61.3, 55.9, 39.4; IR
(KBr) (nmax, cm
1): 3303 (NH), 1669 (C]O), 1591 (C]N), 691
(CeCl); EI-MS, m/z: 420 (Mþ).
2.3.10. 3-(4-Aminophenyl)-N-(2-chlorophenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4j)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.07 (1H, dd, J ¼ 3.89,
11.0 Hz, Ha), 3.76 (1H, dd, J ¼ 3.99, 11.02 Hz, Hb), 3.79 (3H, s,
OCH3), 5.42 (1H, t, J ¼ 8.03 Hz, Hx), 6.52 (2H, s, NH2), 7.02e7.04
(2H, d, J¼ 8.77 Hz, ArH), 7.67e7.81 (8H,m, ArH), 8.06e8.08 (2H, d,
J ¼ 8.73 Hz, ArH), 10.19 (1H, s, CONH); IR (KBr) (nmax, cm1): 3310
(NH), 1678 (C]O), 1591 (C]N), 694 (CeCl); EI-MS,m/z: 420 (Mþ).
2.3.11. 3-(4-Aminophenyl)-N-(4-bromophenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4k)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.03 (1H, dd, J ¼ 3.79,
11.14 Hz, Ha), 3.78 (1H, dd, J ¼ 3.92, 11.91 Hz, Hb), 3.83 (3H, s,OCH3), 5.41 (1H, t, J ¼ 8.91 Hz, Hx), 6.56 (2H, s, NH2), 7.02e7.04
(2H, d, J ¼ 8.33 Hz, ArH), 7.64e7.77 (8H, m, ArH), 8.09e8.11 (2H,
d, J ¼ 8.77 Hz, ArH), 10.19 (1H, s, CONH); IR (KBr) (nmax, cm1):
3310 (NH), 1672 (C]O), 1591 (C]N), 598 (CeBr); EI-MS, m/z:
465 (Mþ1)þ.
2.3.12. 3-(4-Aminophenyl)-N,5-bis(4-methoxyphenyl)-4,5-
dihydro-1H–5-pyrazole-1-carboxamide (4l)
1H NMR (400 MHz, DMSO d6): dH (ppm) 3.07 (1H, dd, J ¼ 3.99,
11.02 Hz, Ha), 3.78 (1H, dd, J ¼ 3.97, 11.01 Hz, Hb), 3.82 (6H, s,
OCH3), 5.41 (1H, t, J ¼ 8.33 Hz, Hx), 6.51 (2H, s, NH2), 7.02e7.04
(2H, d, J ¼ 8.39 Hz, ArH), 7.68e7.79 (8H, m, ArH), 8.09e8.12 (2H,
d, J ¼ 8.77 Hz, ArH), 10.19 (1H, s, CONH); IR (KBr) (nmax, cm1):
3304 (NH), 1679 (C]O), 1596 (C]N); EI-MS, m/z: 416 (Mþ).
2.4. In vitro antimycobacterial activity
All the compounds were screened for their in vitro anti-
mycobacterial activity against Mycobacterium tuberculosis
(MTB) H37Rv. The primary screening was carried out by agar
dilution method using double dilution technique recom-
mended by the National Committee for Clinical Laboratory
Standards (Heifets et al., 1989). Isoniazid and thiacetazone
were used as standard drugs. MTB H37Hv was grown in
Middlebrook 7H11 broth medium supplemented with 10%
OADC (oleic acid, albumin, dextrose and catalase, 1, 10,
100 mg/L). In brief, 103 and 104 colony forming unit (CFU) were
inoculated into 7H11 medium. The minimum inhibitory
concentration (MIC) was defined as the minimum concen-
tration of compound required to 90% inhibition of bacterial
growth.3. Results and discussion
3.1. Chemistry
3-(4-Aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide (4a-l) described in
the present study is shown in Table 1 and their
synthetic protocol is summarized in Scheme 1. In the
initial step 4-aminoacetophenone (0.05 mol) with 4-
methoxybenzaldehyde (0.05 mol) in diluted methanolic so-
dium hydroxide solution was stirred at room temperature
to obtain the intermediate (2E)-1-(4-aminophenyl)-3-(4-
methoxyphenyl)prop-2-ene-1-one (3) following Claisen
Schmidt condensation reaction. In the final step the
intermediate 3 was refluxed with semicarbazide/thio-
semicarbazide/substituted phenyl semicarbazides in glacial
acetic acid furnished the title compounds (4a-l). The
substituted phenyl semicarbazide was synthesized as per the
method reported earlier (Amir et al., 2010). The reaction was
monitored throughout by thin layer chromatography (TLC)
using mobile phase either acetone/benzene (1:9) or toluene/
ethylacetate/formic acid (5:4:1). The yields of the compounds
were ranging between 59 and 82% after recrystallization with
absolute ethanol. The compoundswere characterization by 1H
NMR, IR andmass spectral data. The purity of the compounds
was checked by elemental analysis and is given in Table 1. The
IR spectra of the compounds afforded pyrazoline C]N
Table 1 e Physical constants and elemental analysis of 3-(4-aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide analogues (4a-l).
S. No. Compound Ar % Yield Mp (C) MW MF Elemental analysis (Cal./Ana.)
1. 4a e 82 160e162 326.41 C17H18N4OS (Thitipone et al., 2013)
2. 4b H 78 200e202 310.35 C17H18N4O2 C (65.79) 65.82 H (5.85) 5.82 N (18.05) 18.02
3. 4c Phenyl- 72 192e194 386.44 C23H22N4O2 (Sayed et al., 1996)
4. 4d 4-Methylphenyl 64 196e198 400.47 C24H24N4O2 C (71.98) 71.99 H (6.04) 6.03 N (13.99) 13.96
5. 4e 2-Methylphenyl- 62 198e200 400.47 C24H24N4O2 C (71.98) 71.96 H (6.04) 6.07 N (13.99) 13.97
6. 4f 2,4-Dimethylphenyl- 66 176e178 414.49 C25H26N4O2 C (72.44) 72.42 H (6.32) 6.33 N (13.52) 13.50
7. 4g 2,6-Dimethylphenyl- 68 172e174 414.50 C25H26N4O2 C (72.44) 72.45 H (6.32) 6.31 N (13.52) 13.51
8. 4h 4-Fluorophenyl- 74 180e182 404.43 C23H21FN4O2 C (68.30) 68.31 H (5.23) 5.25 N (13.85) 13.82
9. 4i 4-Chlorophenyl- 79 190e192 420.89 C23H21ClN4O2 C (65.63) 65.59 H (5.03) 5.05 N (13.31) 13.32
10. 4j 2-Chlorophenyl- 61 202e204 420.89 C23H21ClN4O2 C (65.63) 65.60 H (5.03) 5.06 N (13.31) 13.29
11. 4k 4-Bromophenyl- 59 205e207 465.34 C23H21BrN4O2 C (59.36) 56.39 H (4.55) 4.53 N (12.04) 12.02
12. 4l 4-Methoxyphenyl- 63 188e190 416.47 C24H24N4O3 C (69.21) 69.19 H (5.81) 5.83 N (13.45) 13.42
Mp, melting point; MW, molecular weight; MF, molecular formula.
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3302e3314 cm1 and C]O stretching at 1665e1680 cm1
bands. The 1HNMRof the title compoundswere verified on the
basis of their chemical shifts, multiplicities and coupling
constants in DMSO-d6 using TMS as internal standard. The
spectral showed singlet at d 2.09 and 2.35 ppm corresponding
toCH3; doublet doublet at d 3.01e3.07ppmand d 3.77e3.78 ppm
corresponding to twomagnetically non equivalent protons (Ha
and Hb) of methylene due to ring closure; as singlet at
d 3.77e3.78 ppm corresponding to OCH3; a triplet/multiplet at
d 5.41e5.45 ppm corresponding to vicinal methine proton (Hx)
due to methylene protons Ha (upfield H of CH2) and Hb
(downfield H of CH2); a broad singlet at d 6.52 ppm corre-
sponding to NH2; doublets and multiplet at d 6.84e8.13 ppm
corresponding to aromatic protons and a singlet at
d 10.14e10.29 corresponding to CONH. Themass spectra of theNH2
O
+
H
O
O
1 2
MeO
Scheme 1 e Protocol for the synthescompounds showed the molecular ion peaks corresponding
to their molecular formulae.
3.2. Antimycobacterial activity
All the synthesized compounds were tested for in vitro anti-
tubercular activity against MTB H37Rv. The minimum inhibi-
tory concentrations (MICs) recorded were ranging between
7.41 and >120.63 mM. The activity of the synthesized com-
pounds was found to be moderate to weak when compared
with the standard drugs. The compound 4i showed moderate
activity with MIC of 7.41 mM, followed by compound 4j with
MIC of 14.82 mM. The compounds 4h and 4a showed MICs of
15.45 and 19.15 mM respectively, while rest of the compounds
(4b-g, 4k, and 4l) showed weak activities. The MICs for the
standards were recorded as 0.91 mM (isoniazid) and 0.53 mMN N
NH
X Ar
O
NH2
Ha Hb
Hx
NH2
O
O
3
H/NaOH
AcOH ArNHCXNHNH2
4a-l
X = S/O
is of pyrazoline analogues (4a-l).
Table 2 e Antimycobacterial activity of 3-(4-
aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide analogues (4a-
l).
S. No. Compound MIC (mg/mL)a MIC (mM)a
1. 4a 6.25 19.15
2. 4b 25 88.55
3. 4c 12.5 32.35
4. 4d 25 62.42
5. 4e 37.5 93.64
6. 4f >50 >120.63
7. 4g 50 120.63
8. 4h 6.25 15.45
9. 4i 3.12 7.41
10. 4j 6.25 14.82
11. 4k 12.5 26.86
12. 4l 12.5 30.01
13. Isoniazid 0.125 0.91
14. Thiacetazone 0.125 0.53
a MIC ¼ minimum inhibitory concentration, that is, the lowest
concentration to inhibit 90% of Mycobacterium tuberculosis H37Rv
growth; Isoniazid and thiacetazone were used as standard.
b e n i - s u e f u n i v e r s i t y j o u r n a l o f b a s i c a n d a p p l i e d s c i e n c e s 4 ( 2 0 1 5 ) 4 1e4 6 45(thiacetazone). The structure activity relationship established
showed that electron releasing group (methyl and methoxy)
on the N-aryl ring decreased activity while electronegative
group (chloro, fluoro and bromo) increased the activity. The
antitubercular activity was found to be maximum when 4-
chloro group was present on N-aryl ring. The anti-
mycobacterial activity is given in Table 2.3.3. Toxicity prediction by Osiris
All these compounds were subjected to toxicity (mutagenic,
tumorigenic, irritant and reproductive effect) risks prediction
studies byOsiris software (http://www.organic-chemistry.org/
prog/peo/). The toxicity risks prediction studies showed that
all these compoundswere devoid of any toxicity risks (Table 3).Table 3 e Prediction of toxicity risks of 3-(4-
aminophenyl)-5-(4-methoxyphenyl)-4,5-dihydro-1H-
pyrazole-1-carboxamide/carbothioamide analogues (4a-
l).
Compound Prediction of toxicity risk by Osiris
MUT TUM IRRI REP
4a e e e e
4b e e e e
4c e e e e
4d e e e e
4e e e e e
4f e e e e
4g e e e e
4h e e e e
4i e e e e
4j e e e e
4k e e e e
4l e e e e
MUT ¼ mutagenic, TUM ¼ tumorigenic, IRRI ¼ irritant,
REP ¼ reproductive effect. A dash () indicates no effect.4. Conclusion
All the compoundsweresynthesized in satisfactoryyields. The
antitubercular activity of the compounds showedmoderate to
weak activities. 3-(4-Aminophenyl)-N-(4-chlorophenyl)-5-(4-
methoxyphenyl)-4,5-dihydro-1H-pyrazole-1-carboxamide (4i)
showedmoderate antitubercular activity with MIC of 7.41 mM.
The pyrazoline derivatives discovered in this study can be
further modified to increase the antitubercular activity.Acknowledgement
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